インフルエンザ診断の世界市場：市場規模・シェア分析 (製品別・検査の種類別・エンドユーザー別)、産業の需要予測 (～2030年)

市場概要

世界のインフルエンザ診断産業は、2023年に9億4,690万米ドルの規模に達し、2030年には16億310万米ドルに急増すると予測され、予測期間中のCAGRは7.9%です。

インフルエンザ分析ソリューションの需要は、インフルエンザによって悪化する慢性疾患の増加、高齢化人口の増加、この病気の蔓延を追跡するための政府イニシアチブの増加などの結果として急増すると推定されます。感染に対する技術的に複雑な診断ツールの成長も、この業界の大きな推進力となっています。

主な洞察

2023年には、検査キットと試薬のカテゴリーが60%の市場シェアを占めました。

これは、これらの病気が現在より一般的であり、早期診断に対する注目度が顕著に高まっているためです。

2023年には、従来型カテゴリーが40%のシェアで業界をリードしました。

このカテゴリーに属するインフルエンザ迅速診断検査は、使用が簡単で結果が早いため、最も高い収益を上げました。

2023年には、北米地域が売上シェアの65%を占めましたが、これは政府による広範な監視、トップ企業の存在、技術的改善によるものです。

欧州連合 (EU) は、人口の高齢化が進んでおり、2021年には5分の1以上が65歳以上となることから、かなりのシェアを占めると予測されています。

当レポートでは、世界のインフルエンザ診断の市場について分析し、市場の基本構造・最新情勢や主な促進・抑制要因、世界全体および地域別・主要国の市場規模の動向見通し (金額ベース、2017～2030年)、製品別・検査の種類別・エンドユーザー別の詳細動向、現在の市場競争の状況、主要企業のプロファイルなどを調査しております。

目次

第1章 調査範囲

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場指標

第5章 業界の展望

• 市場力学
  • 動向
  • 促進要因
  • 抑制要因/課題
  • 促進要因/抑制要因の影響分析
• 新型コロナウイルス感染症 (COVID-19) の影響
• ポーターのファイブフォース分析

第6章 世界市場

• 概要
• 市場収益：製品別 (2017～2030年)
• 市場収益：検査の種類別 (2017～2030年)
  • 従来型診断検査市場の収益：種類別 (2017年～2030年)
  • 分子診断検査市場の収益：種類別 (2017年～2030年)
• 市場収益：エンドユーザー別 (2017～2030年)
• 市場収益：地域別 (2017～2030年)

第7章 北米市場

• 概要
• 市場収益：製品別 (2017～2030年)
• 市場収益：検査の種類別 (2017～2030年)
  • 従来型診断検査市場の収益：種類別 (2017年～2030年)
  • 分子診断検査市場の収益：種類別 (2017年～2030年)
• 市場収益：エンドユーザー別 (2017～2030年)
• 市場収益：国別 (2017～2030年)

第8章 欧州市場

第9章 アジア太平洋市場

第10章 ラテンアメリカ市場

第11章 中東・アフリカ市場

第12章 米国市場

• 概要
• 市場収益：製品別 (2017～2030年)
• 市場収益：検査の種類別 (2017～2030年)
  • 従来型診断検査市場の収益：種類別 (2017年～2030年)
  • 分子診断検査市場の収益：種類別 (2017年～2030年)
• 市場収益：エンドユーザー別 (2017～2030年)

第13章 カナダ市場

第14章 ドイツ市場

第15章 フランス市場

第16章 英国市場

第17章 イタリア市場

第18章 スペイン市場

第19章 日本市場

第20章 中国市場

第21章 インド市場

第22章 オーストラリア市場

第23章 韓国市場

第24章 ブラジル市場

第25章 メキシコ市場

第26章 サウジアラビア市場

第27章 南アフリカ市場

第28章 アラブ首長国連邦 (UAE) 市場

第29章 競合情勢

• 市場参入企業とその提供製品/サービスの一覧
• 主要企業の競合ベンチマーク
• 主要企業の製品ベンチマーク
• 最近の戦略展開状況

第30章 企業プロファイル

• 3M Company
• Abbott Laboratories Inc.
• Becton, Dickinson and Company
• Meridian Bioscience Inc.
• QuidelOrtho Corporation
• F. Hoffmann-La Roche Ltd.
• SA Scientific Ltd.
• Sekisui Diagnostics LLC
• Thermo Fisher Scientific Inc.
• Hologic Inc.

第31章 付録

Market Overview

The worldwide influenza diagnostics industry generated USD 946.9 million in 2023, which is projected to surge to USD 1,603.1 million by 2030, experiencing a 7.9% CAGR during the projection period.

The requirement for influenza analysis solutions is estimated to surge as a outcome of the growing occurrence of chronic illnesses, several of which are deteriorated by the flu; rising aged populace, and growing government initiatives to track the spread of this illness. The growth of technically complex diagnostic tools for contamination is another major propeller for the industry.

An outbreak of flu can also be a global issue. As a result, huge amounts of R&D initiatives are launched for detection and drug improvement. In the majority of cases, the main research focus is the production of tests that can give fast and precise results on flu viruses in the quickest amount of time.

In 2019, the Centres for Collaborative Research on Influenza Vaccine Innovations (CIVICS) program, which is administered by the U.S. National Institute of Allergy and Infectious Diseases (NIAID), was established to finance a variety of research initiatives pertaining to influenza epidemiology. Generously by NIAID (NIMB), the budgeted amount was USD 51 million emerged as the result of the first year of CIVIC's (Center for Integration of Veterans into the Civic Community) launch.

Key Insights

In 2023, the Test kits and reagent category held a leading market share of 60%.

This is due to the fact that these ailments are currently more common and with a notable rising attention towards early diagnosis.

However, points like ease of access without the necessity of writing a prescription (readily available on the market through pharmacies, retail stores, and online channels), ease of use, quick effect towards weight loss results, and affordable costs result in the growth of this category.

Together with the practical over-the-kit tests, the flu spread can be stopped because the isolated testing can be done without any contact with a suspected carrier.

Point-of-care testing allows people to economize by sending for professionals who are called in to conduct the tests. They also enjoy the tests being easy to conduct by themselves.

In 2023, the traditional category led the industry with a share of 40%.

The category is projected to experience a higher CAGR over the projection period.

Rapid influenza diagnostic tests within this category generated the highest revenue because of their simple use and fast results.

Augmented need for patient handling and surveillance testing for contagions in clinical settings.

Numerous RIDTs are accepted for use at houses and offices, with sanction from CLIA for usage in point-of-care services.

In 2023, the North American region held 65% of the revenue share, because of wide government surveillance, the existence of top companies, and technical improvements.

Well-recognized healthcare infrastructure and helpful reimbursement guidelines propel industry development.

European Union is projected to have a substantial share because of its aging populace, with more than one-fifth being 65 years or more in 2021.

Surging the possibility of flu in elders has led to WHO's recommendation of vaccinating senior people.

Table of Contents

Chapter 1. Research Scope

• 1.1. Research Objectives
• 1.2. Market Definition
• 1.3. Analysis Period
• 1.4. Market Size Breakdown by Segments
  • 1.4.1. Market size breakdown, by product
  • 1.4.2. Market size breakdown, by test type
  • 1.4.3. Market size breakdown, by end user
  • 1.4.4. Market size breakdown, by region
  • 1.4.5. Market size breakdown, by country
• 1.5. Market Data Reporting Unit
  • 1.5.1. Value
• 1.6. Key Stakeholders

Chapter 2. Research Methodology

• 2.1. Secondary Research
  • 2.1.1. Paid
  • 2.1.2. Unpaid
  • 2.1.3. P&S Intelligence database
• 2.2. Primary Research
• 2.3. Market Size Estimation
• 2.4. Data Triangulation
• 2.5. Currency Conversion Rates
• 2.6. Assumptions for the Study
• 2.7. Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Market Indicators

Chapter 5. Industry Outlook

• 5.1. Market Dynamics
  • 5.1.1. Trends
  • 5.1.2. Drivers
  • 5.1.3. Restraints/challenges
  • 5.1.4. Impact analysis of drivers/restraints
• 5.2. Impact of COVID-19
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Bargaining power of buyers
  • 5.3.2. Bargaining power of suppliers
  • 5.3.3. Threat of new entrants
  • 5.3.4. Intensity of rivalry
  • 5.3.5. Threat of substitutes

Chapter 6. Global Market

• 6.1. Overview
• 6.2. Market Revenue, by Product (2017-2030)
• 6.3. Market Revenue, by Test Type (2017-2030)
  • 6.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
  • 6.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
• 6.4. Market Revenue, by End User (2017-2030)
• 6.5. Market Revenue, by Region (2017-2030)

Chapter 7. North America Market

• 7.1. Overview
• 7.2. Market Revenue, by Product (2017-2030)
• 7.3. Market Revenue, by Test Type (2017-2030)
  • 7.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
  • 7.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
• 7.4. Market Revenue, by End User (2017-2030)
• 7.5. Market Revenue, by Country (2017-2030)

Chapter 8. Europe Market

• 8.1. Overview
• 8.2. Market Revenue, by Product (2017-2030)
• 8.3. Market Revenue, by Test Type (2017-2030)
  • 8.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
  • 8.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
• 8.4. Market Revenue, by End User (2017-2030)
• 8.5. Market Revenue, by Country (2017-2030)

Chapter 9. APAC Market

• 9.1. Overview
• 9.2. Market Revenue, by Product (2017-2030)
• 9.3. Market Revenue, by Test Type (2017-2030)
  • 9.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
  • 9.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
• 9.4. Market Revenue, by End User (2017-2030)
• 9.5. Market Revenue, by Country (2017-2030)

Chapter 10. LATAM Market

• 10.1. Overview
• 10.2. Market Revenue, by Product (2017-2030)
• 10.3. Market Revenue, by Test Type (2017-2030)
  • 10.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
  • 10.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
• 10.4. Market Revenue, by End User (2017-2030)
• 10.5. Market Revenue, by Country (2017-2030)

Chapter 11. MEA Market

• 11.1. Overview
• 11.2. Market Revenue, by Product (2017-2030)
• 11.3. Market Revenue, by Test Type (2017-2030)
  • 11.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
  • 11.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
• 11.4. Market Revenue, by End User (2017-2030)
• 11.5. Market Revenue, by Country (2017-2030)

Chapter 12. U.S. Market

• 12.1. Overview
• 12.2. Market Revenue, by Product (2017-2030)
• 12.3. Market Revenue, by Test Type (2017-2030)
  • 12.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
  • 12.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
• 12.4. Market Revenue, by End User (2017-2030)

Chapter 13. Canada Market

• 13.1. Overview
• 13.2. Market Revenue, by Product (2017-2030)
• 13.3. Market Revenue, by Test Type (2017-2030)
  • 13.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
  • 13.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
• 13.4. Market Revenue, by End User (2017-2030)

Chapter 14. Germany Market

• 14.1. Overview
• 14.2. Market Revenue, by Product (2017-2030)
• 14.3. Market Revenue, by Test Type (2017-2030)
  • 14.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
  • 14.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
• 14.4. Market Revenue, by End User (2017-2030)

Chapter 15. France Market

• 15.1. Overview
• 15.2. Market Revenue, by Product (2017-2030)
• 15.3. Market Revenue, by Test Type (2017-2030)
  • 15.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
  • 15.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
• 15.4. Market Revenue, by End User (2017-2030)

Chapter 16. U.K. Market

• 16.1. Overview
• 16.2. Market Revenue, by Product (2017-2030)
• 16.3. Market Revenue, by Test Type (2017-2030)
  • 16.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
  • 16.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
• 16.4. Market Revenue, by End User (2017-2030)

Chapter 17. Italy Market

• 17.1. Overview
• 17.2. Market Revenue, by Product (2017-2030)
• 17.3. Market Revenue, by Test Type (2017-2030)
  • 17.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
  • 17.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
• 17.4. Market Revenue, by End User (2017-2030)

Chapter 18. Spain Market

• 18.1. Overview
• 18.2. Market Revenue, by Product (2017-2030)
• 18.3. Market Revenue, by Test Type (2017-2030)
  • 18.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
  • 18.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
• 18.4. Market Revenue, by End User (2017-2030)

Chapter 19. Japan Market

• 19.1. Overview
• 19.2. Market Revenue, by Product (2017-2030)
• 19.3. Market Revenue, by Test Type (2017-2030)
  • 19.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
  • 19.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
• 19.4. Market Revenue, by End User (2017-2030)

Chapter 20. China Market

• 20.1. Overview
• 20.2. Market Revenue, by Product (2017-2030)
• 20.3. Market Revenue, by Test Type (2017-2030)
  • 20.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
  • 20.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
• 20.4. Market Revenue, by End User (2017-2030)

Chapter 21. India Market

• 21.1. Overview
• 21.2. Market Revenue, by Product (2017-2030)
• 21.3. Market Revenue, by Test Type (2017-2030)
  • 21.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
  • 21.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
• 21.4. Market Revenue, by End User (2017-2030)

Chapter 22. Australia Market

• 22.1. Overview
• 22.2. Market Revenue, by Product (2017-2030)
• 22.3. Market Revenue, by Test Type (2017-2030)
  • 22.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
  • 22.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
• 22.4. Market Revenue, by End User (2017-2030)

Chapter 23. South Korea Market

• 23.1. Overview
• 23.2. Market Revenue, by Product (2017-2030)
• 23.3. Market Revenue, by Test Type (2017-2030)
  • 23.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
  • 23.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
• 23.4. Market Revenue, by End User (2017-2030)

Chapter 24. Brazil Market

• 24.1. Overview
• 24.2. Market Revenue, by Product (2017-2030)
• 24.3. Market Revenue, by Test Type (2017-2030)
  • 24.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
  • 24.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
• 24.4. Market Revenue, by End User (2017-2030)

Chapter 25. Mexico Market

• 25.1. Overview
• 25.2. Market Revenue, by Product (2017-2030)
• 25.3. Market Revenue, by Test Type (2017-2030)
  • 25.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
  • 25.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
• 25.4. Market Revenue, by End User (2017-2030)

Chapter 26. Saudi Arabia Market

• 26.1. Overview
• 26.2. Market Revenue, by Product (2017-2030)
• 26.3. Market Revenue, by Test Type (2017-2030)
  • 26.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
  • 26.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
• 26.4. Market Revenue, by End User (2017-2030)

Chapter 27. South Africa Market

• 27.1. Overview
• 27.2. Market Revenue, by Product (2017-2030)
• 27.3. Market Revenue, by Test Type (2017-2030)
  • 27.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
  • 27.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
• 27.4. Market Revenue, by End User (2017-2030)

Chapter 28. U.A.E. Market

• 28.1. Overview
• 28.2. Market Revenue, by Product (2017-2030)
• 28.3. Market Revenue, by Test Type (2017-2030)
  • 28.3.1. Traditional diagnostic test market revenue, by type (2017-2030)
  • 28.3.2. Molecular diagnostic test market revenue, by type (2017-2030)
• 28.4. Market Revenue, by End User (2017-2030)

Chapter 29. Competitive Landscape

• 29.1. List of Market Players and their Offerings
• 29.2. Competitive Benchmarking of Key Players
• 29.3. Product Benchmarking of Key Players
• 29.4. Recent Strategic Developments

Chapter 30. Company Profiles

• 30.1. 3M Company
  • 30.1.1. Business overview
  • 30.1.2. Product and service offerings
  • 30.1.3. Key financial summary
• 30.2. Abbott Laboratories Inc.
  • 30.2.1. Business overview
  • 30.2.2. Product and service offerings
  • 30.2.3. Key financial summary
• 30.3. Becton, Dickinson and Company
  • 30.3.1. Business overview
  • 30.3.2. Product and service offerings
  • 30.3.3. Key financial summary
• 30.4. Meridian Bioscience Inc.
  • 30.4.1. Business overview
  • 30.4.2. Product and service offerings
  • 30.4.3. Key financial summary
• 30.5. QuidelOrtho Corporation
  • 30.5.1. Business overview
  • 30.5.2. Product and service offerings
  • 30.5.3. Key financial summary
• 30.6. F. Hoffmann-La Roche Ltd.
  • 30.6.1. Business overview
  • 30.6.2. Product and service offerings
  • 30.6.3. Key financial summary
• 30.7. SA Scientific Ltd.
  • 30.7.1. Business overview
  • 30.7.2. Product and service offerings
  • 30.7.3. Key financial summary
• 30.8. Sekisui Diagnostics LLC
  • 30.8.1. Business overview
  • 30.8.2. Product and service offerings
  • 30.8.3. Key financial summary
• 30.9. Thermo Fisher Scientific Inc.
  • 30.9.1. Business overview
  • 30.9.2. Product and service offerings
  • 30.9.3. Key financial summary
• 30.10. Hologic Inc.
  • 30.10.1. Business overview
  • 30.10.2. Product and service offerings
  • 30.10.3. Key financial summary

Chapter 31. Appendix

• 31.1. Abbreviations
• 31.2. Sources and References
• 31.3. Related Reports